Merck KGaA (MRK) Given a €115.00 Price Target by Sanford C. Bernstein Analysts

Merck KGaA (FRA:MRK) received a €115.00 ($136.90) price target from equities researchers at Sanford C. Bernstein in a report released on Wednesday. The firm currently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s target price indicates a potential upside of 28.26% from the company’s current price.

MRK has been the topic of a number of other research reports. Oddo Bhf set a €125.00 ($148.81) target price on Merck KGaA and gave the company a “buy” rating in a research report on Friday, November 10th. JPMorgan Chase & Co. set a €100.00 ($119.05) target price on Merck KGaA and gave the company a “neutral” rating in a research report on Friday, October 6th. Citigroup set a €123.00 ($146.43) target price on Merck KGaA and gave the company a “buy” rating in a research report on Monday, September 25th. Goldman Sachs Group set a €105.00 ($125.00) target price on Merck KGaA and gave the company a “neutral” rating in a research report on Tuesday, September 19th. Finally, UBS Group set a €120.00 ($142.86) target price on Merck KGaA and gave the company a “buy” rating in a research report on Monday, January 8th. Twelve equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of €107.57 ($128.06).

Merck KGaA (FRA MRK) traded down €0.46 ($0.55) during trading hours on Wednesday, reaching €89.66 ($106.74). The company’s stock had a trading volume of 675,971 shares. Merck KGaA has a 12 month low of €87.33 ($103.96) and a 12 month high of €115.00 ($136.90). The stock has a market capitalization of $11,650.00 and a P/E ratio of 21.00.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://stocknewstimes.com/2018/01/19/merck-kgaa-mrk-given-a-115-00-price-target-by-sanford-c-bernstein-analysts.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply